Dr Jorge Mestre-Ferrandiz, OHE's Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence the rate and direction of R&D for medicines, including regulatory approval requirements, the patent system, the economics of R&D, the roles of the public and private sectors, “push” and “pull” incentives, and the influence of capital markets.
Since 1993, OHE has hosted an annual lecture given by an eminent economist or clinician on an important current issue. In 2012, Professor Sir Michael Rawlins spoke on challenges and concepts in developing evidence of effectiveness.
OHE’s Jon Sussex is spoke today on the value of medical research at the 2013 BioWales conference, one of the UK’s largest life sciences conferences. Celebrating its eleventh year, this conference focuses on the links between NHS, industry and academia in delivering tomorrow’s health solutions. Jon’s presentation examined the value of medical research, which involves all three sectors in the UK: public, private and charity.
The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of conjecture. In a recent presentation to the 25th Annual EuroMeeting of the Drug Information Association (DIA), OHE's Jorge Mestre-Ferrandiz presented the results of OHE research into R&D discontinuations.
OHE's Jorge Mestre-Ferrandiz reviewed the results of OHE's recent study on the R&D cost of developing a new drug at a seminar at University College London. Released in December 2012, the study's purpose was to capture and examine in one place the important research on the cost of drug development that had been published over the past 30 years.
How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or for industry understanding of its performance, but because they are a key aspect of the international debate about the reasonableness of pharmaceutical prices and the magnitude of the long-term investments involved. The Office of Health Economics today released a comprehensive study of the cost of R&D for new medicines.
In this OHE lunchtime seminar, Prof Heidi Williams of MIT will present the results of a recent paper using newly-collected data on the sequencing of the human genome by the public Human Genome Project and the private firm Celera to investigate how Celera's gene-level IP influenced subsequent scientific research and product development.
To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of the key aspects of drug development over the next ten years. The conference was attended by over 100 participants from the public and private sectors; speakers and panellists included leaders from drug regulatory agencies, health technology assessment (HTA) groups, payers, the pharmaceutical industry, private foundations, and academia.
OHE and the Pharmaceutical Oncology Initiative (POI) held a workshop to discuss and debate several key issues in oncology modelling. Participating were more than 50 experts from industry, academia and government. The focus of the workshop was three key technical challenges associated with using clinical trial data for anti-cancer medicines and adapting it, in an unbiased fashion, to support decisions about cost-effectiveness.